anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a new Bacillus thurigiensis isolate capable of terminating insect pests of the order Lepedoptera by bringing an effective amount of Bacillus thurigiensis (B.t.) PS81F or its variant into contact with the insect pests. CONSTITUTION: An amount effective to terminate a pest, of B.t. PS81F (NRRL B-18424) or its mutant, e.g. the mutant obtained by mutation induction by ethyl methanesulfonate, is brought into contact with insect pests of the order Lepedoptera. The pest living in a soil is terminated by mixing the B. t. PS81F into granular feeds and placing the granular feeds mixed with the B.t. and containing an attractant on or in the soil when seeds of a plant obviously eaten by the pet is sowed. Further, the insect of the order Lepedoptera is terminated by introducing delta endotoxin genes encoding a protein of 13266 dalton obtained from the B.t. PS81F and having activities against the pest of the order Lepedoptera through suitable vectors into the host microbes (e.g.  Pseudomonas species, Azotobacter species) to transform the microbes and further administrating the transformed microbes to the insect of the order Lepedoptera or the environment of the insect.
The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
The invention provides a propolis tincture for external use and a preparation method thereof. The propolis tincture for external use comprises the following ingredients: 5-30 wt% of propolis liquid with a concentration of 0.02 g/mL, 0.1-0.5 wt% of tea tree oil, 0.1-0.5 wt% of mint essential oil, and the balance consisting of ethanol. The propolis tincture for external use is prepared by mixing the three natural ingredients, has remarkable effect of antibiosis and antiphlogosis, good solubility, and improved purity. By avoiding containing heavy metal and other impurities, the propolis tincture for external use has bright, pure and transparent color. According to the invention, allergenic ingredients in propolis is effectively removed, so that the occurrence of allergy in using is reduced. The preparation method has simple operation.
Mothers and their infants were followed throughout the first two years of the infant's life. Data were collected at enrollment, birth, 3, 6, 9,12, 18 and 24 months from the date of delivery.
A substitute which approximates physiological and rheological properties of natural saliva is prepd. from methocel (hydroxy-propyl-methyl-cellulose), hydroxy-propyl-cellulose or from some other colloid forming cellulose deriv.. A basic 1% soln. is prepd. by adding hot sterilised, distilled, water. A soln. of inorganic salts, active additives, artificial sweeteners, preservatives and flavouring is added to this. The complete soln. aseptically filtered and packaged in plastic bottles fitted with a dosing head. (1pp Dwg.No.0/0)
Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
Upto 85 normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
FIELD: medicine, pharmacology. SUBSTANCE: invention proposes to use the natural complex of collagenolytic proteinases from crab hepatopancreas as an agent regulating the rate of effect of the preparation for injections and the preparation for injections (in the first variant) that has an active component, solvent and an agent regulating the rate of effect. This agent is a natural complex of collagenolytic proteinases obtained from digestive organs of hydrobionts. In the second variant the preparation has an active component and the natural complex of collagenolytic proteinases involving the complex isolated from digestive organs of crustacean, mollusks, echinoderms and coelenterata animals and containing the following collagenolytic proteinases: serine collagenolytic proteinases, metalloproteinases and proteinases containing N-terminal alanines. Invention provides the increase of stability at pH at the range from 5.0 to 9.5 and uses different pharmacological agents and biologically nonactive substances. Invention can be used in supporting therapy, aesthetic medicine and cosmetology. EFFECT: enhanced effectiveness of an agent. 13 cl, 6 ex
PURPOSE:To obtain the titled preparation free from side effect, simply and economically without using a coating polymer, by melting and/or dispersing uniformly a drug and a surface active agent into lipid. CONSTITUTION:1/40-40 times as much lipid [water-insoluble substance having action to delay elution of drug, having preferably (40-150 deg.C) softening point or melting point: hardended oil, paraffin, etc.] as drug by weight is melted under heating at 40-150 deg.C, blended with a drug and 0.01-2.0 times as much a surface active agent (e.g., sucrose fatty acid ester, Tween 80, sodium lauryl sulfate, etc.) as the drug by weight, and, if necessary, an excipien, and lubricant, and uniformly melted and/or dispersed, sprayed and cooled by spray cooling method into the desired particle size, to give a sustained release preparation. A slightly water soluble drug (e.g., FP, IP, etc.) as well as a water-soluble drug (e.g., befunolol hydrochloride, etc.) may be cited as the drug.
1. Technical Result Increase in efficiency of treatment of prostate. 2. Essence The present invention provides 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate of the formula (1) together with processes for preparing, and compositions containing it. The invention also relates to substantially pure anhydrous crystalline polymorphic forms of the free base. The compounds are particularly useful in the treatment of benign prostatic hyperplasia. 3. Field of Application Medicine.
<P>PROBLEM TO BE SOLVED: To provide an antibody-containing food in a form containing an effective amount of antibody, capable of easily being ingested and capable of being retained in oral cavity and to provide a method for producing the food.  <P>SOLUTION: The present invention provides tablet candies or tablets each containing ≥0.1 mass% antibody e.g. derived from milk and a method for producing the tablet candies or the tablets. The method for producing the tablet candies or the tablets comprises tableting a composition containing the antibody under ≤10 ton/cm<SP>2</SP>pressure or putting the composition in a mold, compacting the composition with hands, etc. and demolding the molded product and drying the molded product under an atmosphere of ≤70°C.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The size, number and distribution of diverticula vary greatly in patients with diverticulosis. We aimed to study the association between the morphology of diverticulosis assessed on colonoscopy and the risk of diverticulitis. We performed a retrospective, case-control study of cases with a history of diverticulitis and controls with diverticulosis without diverticulitis matched on sex, age (within 5 years) and year of colonoscopy. Diverticulosis characteristics were obtained from endoscopy reports and were categorized according to severity, extent, number and size. We used conditional logistic regression on matched pairs to calculate the odds of diverticulitis among patients with diverticulosis according to differing morphologic characteristics. We identified 85 cases with computed tomography-documented diverticulitis and 85 matched controls with diverticulosis without a diagnosis of diverticulitis. In cases, 60% had left-sided only diverticulosis, 2% had right-sided only and 38% had both right and left-sided diverticulosis; whereas in controls, the distribution was 53%, 18% and 29%, respectively. Cases were more likely to have large diverticula [odds ratio (OR), 3.33; 95% confidence interval (CI), 1.30-8.56 for left colon only and 1.89, 95% CI, 0.78-4.57 for both right and left]. Similarly, when the severity of diverticulosis was compared between the groups, cases were more likely to have moderate or severe diverticulosis (OR, 3.44; 95% CI, 1.51-7.84 for moderate and OR, 8.87; 95% CI, 2.98-26.37 for severe). Diverticulitis cases were more likely to have large diverticula and severe diverticulosis when compared to controls suggesting that size and severity are novel risk factors for diverticulitis.
PURPOSE:To provide a moisturizing agent having high safety and excellent moisture-absorbing and moisture-retaining properties, and containing an amorphous water-soluble partially deacetylated chitin containing specific amounts of N-acetyl-D-glucosamine and D-glucosamine as constituent components. CONSTITUTION:The objective moisturizing agent contains an amorphous water- soluble partially deacetylated chitin containing (A) N-acetyl-D-glucosamine and (B) D-glucosamine as constituent units, wherein the contents of (A) and (B) are 40-60% and 60-40%, respectively. The moisturizing agent exhibits excellent moisture-absorbing and retaining effects, and imparts the applied material with tackfree moist feeling because of its film-forming property originated from the polymeric structure. It has high safety and can be used as an additive to foods, cosmetics, etc. as well as to shoe polish, paint, paper products, etc. The chitin can be produced from crustaceans such as crab, shrimp, krill, etc. which is abundant in natural resources and has not hitherto been utilized effectively.
Patients receive Shi's traumatology osteopathic manipulative treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments.
Chronic kidney disease (CKD) is a prevalent disease among felids; yet its origin is still poorly understood, and the disease often remains asymptomatic for years, underscoring the need for early diagnosis. This study aimed to investigate the diagnostic value of urinalysis in accurately staging CKD, particularly as routine health checks in large felids often overlook its significance. In this research, ultrasound-guided cystocentesis (UGC) was performed on 50 captive nondomestic felids during routine veterinary health checks under general anesthesia. Urinalysis included microscopic examination of the sediment, measurement of urine specific gravity (USG) and protein to creatinine ratio (UPC). Additional serum kidney markers, such as creatinine and symmetric dimethylarginine, were compared with USG and UPC to assess their diagnostic value as urinary biomarkers. The results demonstrated proteinuria (UPC > 0.4) or borderline proteinuria (UPC 0.2-0.4) in 49% of the animals. Among these cases, 62% were of renal origin, and 38% were postrenal causes. USG was significantly higher in felids with borderline proteinuria compared to those with proteinuria. A moderate, but significant negative correlation between serum parameters and USG was observed, emphasizing the importance of assessing both diagnostic parameters during kidney evaluations. Additionally, felids with CKD have an increased risk of urinary tract infections, necessitating microscopic urinalysis and bacterial culture analysis. Abnormalities, including hematuria, pyuria, crystalluria, and bacteriuria, were found in approximately 38% of cases through microscopical examination of urine. No complications associated with UGC were observed and abnormal findings were detected in 60% of the cases. Based on these results, the authors recommend the inclusion of UGC and urinalysis as standard diagnostic tools in general health checks for nondomestic felids. This approach provides valuable insights into the early detection and staging of CKD, supporting early intervention and supportive medical care to prolong renal health in these animals.
Niacin is a vitamin that has beneficial effects on cholesterol (a type of fat in the blood) when used in high doses. Different people respond differently to cholesterol lowering doses of niacin, some people have a side effect termed flushing (similar to a hot flash) while others do not and some people have more pronounced effects on cholesterol. Endotoxin or lipopolysaccharide (LPS) is a small part of bacteria (that is no longer living) that can cause many of the effects similar to bacterial infections in humans. However, it can be administered in very small amounts to produce a mild inflammatory response much the same as a 'flu-like" illness. Within 1 ½ -3 hours after giving LPS by vein, a response consisting of fever, chills, headache, nausea and vomiting and generalized aches and pains will occur which lasts up to 6-8 hours. In addition to the flu like symptoms, the inflammation causes changes in cholesterol, triglycerides and glucose clearance. Different people respond differently to endotoxin and inflammation. We are performing this study to see if there are genetic factors that predict how people will respond to niacin and to endotoxin and its inflammatory response.
Human papillomavirus (HPV) infection is a sexually transmitted infection which causes cancer, especially cervical cancer. HPV infection and cervical cancer are a public health concern in South Africa. Primary prevention interventions, such as vaccination against cervical cancer, have been rolled out in the country. However, the uptake of the vaccine faces challenges due to various factors. The aim of the review was to identify factors which influence the uptake of the vaccine. A six-step framework developed by Levac, Colquhon and O'Brien was adopted to guide this scoping review. The articles were searched in the following databases: EBSCOhost, PubMed, CINAHL and Google scholar. The search, conducted from May to July 2023 was limited to articles published in English between 2008-2023 and those conducted in Africa. The results showed that most studies were conducted in sub-Saharan Africa, with majority of the studies being from Nigeria. Subthemes were extracted from the articles and categorised under the four themes of the Social Ecological Model. The four themes used from the Social Ecological Model were individual factors; interpersonal factors; community and societal factors, and organisational factors and public policy. The subthemes were socioeconomic and sociodemographic of parents, knowledge, fear and mistrust, family structure and proximity to cancer/STI, misinformation from social media, religion, culture and tradition, free vaccination programme and lack of engagement. The identified gap in literature was a lack of studies of factors which influence HPV vaccination uptake in South Africa and qualitative studies that explore and provide the factors influencing uptake. We conclude that in designing effective interventions for the uptake of HPV vaccines, it is important to consider influential factors that are tailor-made for specific demographics.
The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
Participants in the intervention group will undergo the telerehabilitation TAR program and install and utilise the application on their mobile device, and self-administer the home exercises as prescribed by their physiotherapists. The mobile application uses novel deep learning algorithm on a mobile platform to detect key landmarks on the body for human pose estimation. Participants will be able to perform their rehabilitation exercise with real-time feedback allowing for proper execution of the exercises. The participants will be instructed on the installation and use of the mobile application and will be expected to perform the prescribed exercises independently (using the application) as instructed by their Physiotherapists. This application will be used for the initial 12 weeks of post-op rehabilitation.
OBJECTIVE: To describe adherence to daily somatropin treatment and impact on height velocity within 1 year of treatment start among patients with pediatric growth hormone deficiency in a real-world US population.
METHODS: This retrospective cohort study included pediatric patients aged ≥3 years to <16 years with pediatric growth hormone deficiency prescribed somatropin by a pediatric endocrinologist at a US-based center of excellence between January 1, 2015 and December 31, 2020. Patient data were collected using hospital electronic health records linked to a specialty pharmacy patient prescription records. Adherence, evaluated over 12 months, was measured using the proportion of days covered metric and patients were categorized as adherent if their proportion of days covered ≥80%. Height velocity was annualized to compare across adherent and nonadherent patients.
RESULTS: One hundred eighty-one patients were identified and included in this study, of which 70.2% were male,73.5% were white, and mean age (standard deviation [SD]) at index was 12.1 (2.8). In the height velocity analysis, 174 patients were included and the mean (SD) annualized change in height was 10.2 (5.7) cm/y in the adherent group (n = 108) and 9.8 (7.6) in the nonadherent group (n = 66). The difference in height velocity between the groups was not statistically significant.
CONCLUSIONS: Minor improvements in average height velocity were observed in the patient group who were adherent to somatropin therapy, although not statistically significant. Lack of observed significance may be due to small sample sizes, short observation period, a likely heterogenous population in terms of growth hormone prescribing, data bias due to single-center origin, or potential patient misclassification.
Hypocalcemia has occurred in patients receiving EVENITY. Correct hypocalcemia prior to initiating EVENITY [see Contraindications (4), Adverse Reactions (6.1) and Use in Specific Populations (8.7)].

Monitor patients for signs and symptoms of hypocalcemia. Patients should be adequately supplemented with calcium and vitamin D while on EVENITY [see Dosage and Administration (2.2) and Clinical Studies (14.1)].

Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m2) or receiving dialysis are at greater risk of developing hypocalcemia. Monitor serum calcium and adequately supplement patients who have severe renal impairment or are receiving dialysis with calcium and vitamin D. Instruct patients with severe renal impairment, including those receiving dialysis, about the symptoms of hypocalcemia and the importance of maintaining calcium levels with adequate calcium and vitamin D supplementation.
Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year. Patients also undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.
Gabapentin was evaluated for the management of postherpetic neuralgia (PHN) in two randomized, double-blind, placebo-controlled, multicenter studies. The intent-to-treat (ITT) population consisted of a total of 563 patients with pain for more than 3 months after healing of the herpes zoster skin rash (Table 6).

Each study included a 7- or 8-week double-blind phase (3 or 4 weeks of titration and 4 weeks of fixed dose). Patients initiated treatment with titration to a maximum of 900 mg/day gabapentin over 3 days. Dosages were then to be titrated in 600 to 1200 mg/day increments at 3- to 7-day intervals to the target dose over 3 to 4 weeks. Patients recorded their pain in a daily diary using an 11-point numeric pain rating scale ranging from 0 (no pain) to 10 (worst possible pain). A mean pain score during baseline of at least 4 was required for randomization. Analyses were conducted using the ITT population (all randomized patients who received at least one dose of study medication).

Both studies demonstrated efficacy compared to placebo at all doses tested.

The reduction in weekly mean pain scores was seen by Week 1 in both studies, and were maintained to the end of treatment. Comparable treatment effects were observed in all active treatment arms. Pharmacokinetic/pharmacodynamic modeling provided confirmatory evidence of efficacy across all doses. Figures 1 and 2 show pain intensity scores over time for Studies 1 and 2.

Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 

Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 

The proportion of responders (those patients reporting at least 50% improvement in endpoint pain score compared to baseline) was calculated for each study (Figure 3).

Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies
Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
PURPOSE: A composition containing horse chestnut extract having angiogenesis-inhibiting activity as an effective component is provided. The horse chestnut extract has excellent angiogenesis-inhibiting effect and thus can be effectively used as a tumor suppressor and a cancer metastasis suppressant and in the treatment of ophthalmic disease caused by angiogenesis and various diseases related to angiogenesis. CONSTITUTION: An angiogenesis-inhibiting composition contains a horse chestnut extract. For an example, 500g of horse chestnut leaves and 200g of horse chestnut seeds are respectively extracted in 80% methanol at 50deg.C for 12hr. The extract is filtered and concentrated to produce 120g of a chestnut leaf extract and 53g of chestnut seed extract. A syrup product contains 2g of chestnut extract powder, 0.8g of saccharin, 25.4g of saccharide, 8.0g of glycerin, 0.04g of flavorings, 4.0g of ethanol, 0.4g of sorbic acid and a suitable amount of distilled water. A unit dose of the extract is preferably 5mg to 2g, more preferably 10mg to 1g.